SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Eaton Bruce

(Last)

(First)

(Middle)

C/O EDITAS MEDICINE, INC.

11 HURLEY ST.

(Street)

CAMBRIDGE

02141

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
07/23/2021

3. Issuer Name and Ticker or Trading Symbol
Editas Medicine, Inc. [ EDIT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
EVP, Chief Business Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	28,313⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽²⁾	02/04/2028	Common Stock	110,000	33.98	D
Stock Option (right to buy)	⁽³⁾	02/05/2029	Common Stock	48,750	21.1	D
Stock Option (right to buy)	⁽⁴⁾	02/05/2030	Common Stock	45,007	28.05	D
Stock Option (right to buy)	⁽⁵⁾	03/01/2031	Common Stock	17,133	45.69	D

Explanation of Responses:

1. Reflects (i) 9,830 shares of common stock and (ii) 18,483 shares of common stock received by the Reporting Person in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, of which (A) 3,555 shares are scheduled to vest over four years with 25% of the units having vested on February 6, 2020 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 6, 2023, (B) 5,157 shares are scheduled to vest over four years with 25% of the units having vested on February 6, 2021 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 6, 2024, (C) 4,289 shares are scheduled to vest in full on March 31, 2022, and (D) 5,482 shares are scheduled to vest over four years with 25% of the units vesting on March 2, 2022 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2025.

2. This option was granted on February 5, 2018 and is scheduled to vest over four years, with 25% of the shares having vested on January 22, 2019 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through January 22, 2022.

3. This option was granted on February 6, 2019 and is scheduled to vest over four years in equal monthly installments beginning on March 6, 2019 through February 6, 2023.

4. This option was granted on February 6, 2020 and is scheduled to vest over four years in equal monthly installments beginning on March 6, 2020 through February 6, 2024.

5. This option was granted on March 2, 2021 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2021 through March 2, 2025.

	/s/ Bruce Eaton	07/30/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.